RECARBRIO 500 mg Powder for Solution for Infusion

RECARBRIO 500 is a powerful, broad-spectrum antibiotic designed to combat serious bacterial infections, particularly those caused by carbapenem-resistant pathogens. Developed by Merck Sharp & Dohme (MSD), it combines three active ingredients: imipenem, cilastatin, and relebactam. Imipenem is a carbapenem antibiotic known for its potent antibacterial activity against a wide range of bacteria. Cilastatin prevents the breakdown of imipenem in the kidneys, ensuring higher and more prolonged levels of imipenem in the body. Relebactam is a novel beta-lactamase inhibitor that restores the activity of imipenem against certain resistant bacteria producing specific types of beta-lactamase enzymes.

Benefits of Use

• Effective against a broad spectrum of gram-negative and some gram-positive bacteria, including multi-drug resistant strains.
• Specifically targets difficult-to-treat infections caused by carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
• Offers a crucial treatment option for severe infections such as complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired bacterial pneumonia (HABP), including ventilator-associated bacterial pneumonia (VABP).
• The combination with relebactam helps overcome bacterial resistance mechanisms, enhancing treatment efficacy.

How to Use

RECARBRIO 500 mg Powder for Solution for Infusion is administered intravenously by a healthcare professional in a hospital or clinical setting. It is not intended for self-administration.

1. The powder must be reconstituted and diluted according to specific guidelines provided in the prescribing information, typically using an appropriate diluent such as 0.9% sodium chloride injection.
2. The dosage and duration of treatment will be determined by a physician based on the patient's condition, the severity of the infection, and renal function.
3. The prepared solution is administered as an intravenous infusion over a specified period, usually 30 minutes.
4. Regular monitoring of the patient's response to treatment and potential side effects is essential throughout the course of therapy.

Caution & Warnings

• Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported. Discontinue immediately if an allergic reaction occurs.
• Central Nervous System (CNS) Effects: Seizures, myoclonus, and other CNS adverse reactions have been reported, particularly in patients with CNS disorders or impaired renal function.
• Clostridioides difficile-Associated Diarrhea (CDAD): CDAD has been reported with nearly all antibacterial agents, including RECARBRIO. Evaluate if diarrhea occurs.
• Drug Interactions: Co-administration with valproic acid or divalproex sodium is generally not recommended, as it may reduce valproic acid concentrations and increase the risk of seizures.
• Renal Impairment: Dosage adjustments are required in patients with impaired renal function.
• Pregnancy and Lactation: Use during pregnancy and lactation only if clearly needed and the potential benefits outweigh the potential risks, as determined by a healthcare provider.

Ingredients

• Active Ingredients: Imipenem, Cilastatin, Relebactam
• Each vial contains: Imipenem 500 mg, Cilastatin 500 mg, Relebactam 250 mg

Product Details

• Form: Powder for solution for infusion
• Route of Administration: Intravenous (IV)
• Manufacturer: Merck Sharp & Dohme (MSD)
• Storage: Store at controlled room temperature (below 25°C) and protect from light.
• Packaging: Available as a pack of 25 vials.